辛伐他汀对TGF-β诱导的卵巢癌上皮间质转化的影响
Effects of simvastatin on TGF-β induced epithelial-to-mesenchymal transition in ovarian cancer

DOI: 10.6040/j.issn.1671-7554.0.2018.171

Keywords: 卵巢癌,上皮间质转化,辛伐他汀,转化生长因子-β,SPAG9/JNK信号通路,
Ovarian cancer,SPAG9/JNK pathway,Simvastatin,Epithelial-to-mesenchymal transition,Transforming growth factor-β

Full-Text   Cite this paper   Add to My Lib

Abstract:

References

[1]	Cuello F M, Kato C S, Díaz S D, et al. Effects of statins in cancer[J]. Rev Med Chil, 2013, 141(2): 227-236.
[2]	Pallet N, Thervet E, Anglicheau D. c-Jun-N-terminal kinase signaling is involved in cyclosporine-induced epithelial phenotypic changes[J]. J Transplant, 2012, 2012: 348604.
[3]	Giancotti FG. Mechanisms governing metastatic dormancy and reactivation[J]. Cell, 2013, 155(4): 750-764.
[4]	Maeda M, Johnson KR, Wheelock MJ. Cadherin switching: essential for behavioral but not morphological changes during an epithelium-to-mesenchyme transition[J]. J Cell Sci, 2005, 118(Pt 5): 873-887.
[5]	Robinson E, Nandi M, Wilkinson LL, et al. Preclinical evaluation of statins as a treatment for ovarian cancer[J]. Gynecol Oncol, 2013, 129(2): 417-424.
[6]	Stine JE, Guo H, Sheng X, et al. The HMG-CoA reductase inhibitor, simvastatin, exhibits antimetastatic and anti-tumorigenic effects in ovarian cancer[J]. Oncotarget, 2015, 71: 946-960.
[7]	Chen XF, Zhang HJ, Wang HB, et al. Transforming growth factor-β1 induces epithelial-to-mesenchymal transition in human lung cancer cells via PI3K/Akt and MEK/Erk1/2 signaling pathways[J]. Mol Biol Rep,2012, 39(4): 3549-3556.
[8]	Zhang L, Yan L, Zhao X, et al. SPAG9 promotes endometrial carcinoma cell invasion through regulation of genes related to the epithelial-mesenchymal transition[J]. Eur J Gynaecol Oncol, 2016, 37(3): 312-319.
[9]	Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions[J]. Nat Rev Mol Cell Biol, 2006, 7(2): 131-142.
[10]	Neel DS, Bivona TG. Secrets of drug resistance in NSCLC exposed by new molecular definition of EMT[J]. Clin Cancer Res, 2013, 19(1): 3-5.
[11]	Wendt MK, Tian M, Schiemann WP. Deconstructing the mechanisms and consequences of TGF-beta-induced EMT during cancer progression[J]. Cell Tissue Res, 2012, 347(1): 85-101.
[12]	Lee J, Jung KH, Park YS, et al. Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin(FOLFIRI)as first-line chemotherapy inmetastatic colorectal patients: a multicenter phase II study[J]. Cancer Chemother Pharmacol, 2009, 64(4): 657-663.
[13]	Schointuch MN, Gilliam TP, Stine JE, et al. Simvastatin, an HMGCoA reductase inhibitor, exhibits anti-metastatic and anti-tumorigenic effects in endometrial cancer[J]. Gynecol Oncol, 2014, 134(2): 346-355.
[14]	Liu Q, Zhang Y, Mao H, et al. A crosstalk between the Smad and JNK signaling in the TGF-beta-induced epithelial-mesenchymal transition in rat peritoneal mesothelial cells[J]. PLoS One, 2012, 7(2): e32009.
[15]	Avruch J. MAP kinase pathways: the first twenty years[J]. Biochim Biophys Acta, 2007, 1773(8): 1150-1160.
[16]	Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
[17]	Chakrabarti R, Hwang J, Andres Blanco M, et al. Elf5 inhibits the epithelial mesenchymal transition in mammary gland development and breastcancer metastasis by transcriptionally repressing Snail2[J]. Nat Cell Biol, 2012, 14(11): 1212-1222.
[18]	Zhang HJ, Wang HY, Zhang HT, et al. Transforming growth factor-β1 promotes lung adenocarcinoma invasion and metastasis by epithelial-to-mesenchymal transition[J]. Mol Cell Biochem, 2011, 355(1-2): 309-314.
[19]	Rennert G, Rennert HS, Pinchev M, et al. The effect of bisphosphonates on the risk of endometrial and ovarian malignancies[J]. Gynecol Oncol, 2014, 133(2): 309-313.
[20]	Fang Z, Tang Y, Fang J, et al. Simvastatin inhibits renal cancer cell growth and metastasis via AKT/mTOR, ERK and JAK2/STAT3 pathway[J]. PLoS One, 2013, 8(5): e62823.
[21]	Jagadish N, Rana R, Selvi R, et al. Characterization of a novel human sperm-associated antigen 9(SPAG9)having structural homology with c-Jun N-terminal kinase-interacting protein[J]. Biochem J, 2005, 389(Pt 1): 73-82.
[22]	Mirandola L, J Cannon M, Cobos E, et al. Cancer testis antigens:novel biomarkers and targetable proteins for ovarian cancer[J]. Int Rev Immunol, 2011, 30(2-3): 127-137.
[23]	Ha JH, Yan M, Gomathinayagam R, et al. Aberrant expression of JNK-associated leucine-zipper protein, JLP, promotes accelerated growth of ovarian cancer[J]. Oncotarget, 2016, 7(45): 72845-72859.
[24]	Yu P, Yan L, Zhao X, et al. Expression and clinical significance of sperm-associated antigen 9 in patients ith endometrialcarcinoma[J]. Int J Gynecol Cancer, 2012, 22(1): 87-93.

Full-Text